Mohamed Raslan
Impact in
- Toxicology top 10%
- Bioactive Compounds and Antitumor Agents
-
- Nigella sativa pharmacological applications
Papers in
-
- COVID-19 Clinical Research Studies 7
- SARS-CoV-2 and COVID-19 Research 4
-
- Antibiotics Pharmacokinetics and Efficacy 3
- Drug-Induced Hepatotoxicity and Protection 1
- Co-authors
- Mohammed Elmowafy (2 shared papers)Ayman Salama (2 shared papers)Nagwa A. Sabri (19 shared papers)Tapani Viitala (1 shared paper)Wafaa I. El‐Eraky (1 shared paper)Ragab Said (1 shared paper)Sally A. El Awdan (1 shared paper)Mohamed Ali (1 shared paper)
- Journals
- Pharmaceutics (1 paper)Expert Opinion on Drug Safety (1 paper)Vaccines (1 paper)AAPS PharmSciTech (1 paper)Advances in experimental medicine and biology (1 paper)
- Partner nations
- EgyptBrazilUnited States
In The Last Decade
Mohamed Raslan
23 papers receiving 205 citations
Peers
Comparison fields: 5 of 69
- Toxicology 30
- Complementary and alternative medicine 63
- Pharmaceutical Science 49
- Pharmacology 25
- Obstetrics and Gynecology 16
Countries citing papers authored by Mohamed Raslan
This map shows the geographic impact of Mohamed Raslan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohamed Raslan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohamed Raslan more than expected).
Fields of papers citing papers by Mohamed Raslan
This network shows the impact of papers produced by Mohamed Raslan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohamed Raslan. The network helps show where Mohamed Raslan may publish in the future.
Co-authors
The 25 scholars most cited alongside Mohamed Raslan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 108 | |
| 2 | 2021 | 23 | |
| 3 | 2017 | 21 | |
| 4 | 2020 | 17 | |
| 5 | 2021 | 7 | |
| 6 | 2021 | 5 | |
| 7 | 2020 | 3 | |
| 8 | 2023 | 2 | |
| 9 | 2023 | 2 | |
| 10 | 2020 | 2 | |
| 11 | 2022 | 2 | |
| 12 | 2024 | 2 | |
| 13 | 2020 | 2 | |
| 14 | 2024 | 1 | |
| 15 | 2025 | 1 | |
| 16 | 2021 | 1 | |
| 17 | 2021 | 1 | |
| 18 | Management protocols for COVID-19: Will it include targeting ADAM 17. | 2020 | 1 |
| 19 | 2020 | 1 | |
| 20 | 2021 | 1 |
About Mohamed Raslan
Mohamed Raslan is a scholar working on Infectious Diseases, Pharmacology, Pathology and Forensic Medicine, Food Science and Surgery, having authored 27 papers that have together received 206 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers), Heparin-Induced Thrombocytopenia and Thrombosis (2 papers), Gut microbiota and health (2 papers), Analytical Methods in Pharmaceuticals (2 papers), Probiotics and Fermented Foods (2 papers) and Drug-Induced Hepatotoxicity and Protection (1 paper). The work is most often cited by research in Toxicology (30 citations), Complementary and alternative medicine (63 citations), Pharmaceutical Science (49 citations), Pharmacology (25 citations) and Obstetrics and Gynecology (16 citations). Mohamed Raslan has collaborated with scholars based in Egypt, Brazil and United States. Frequent co-authors include Mohammed Elmowafy, Ayman Salama, Nagwa A. Sabri, Tapani Viitala, Wafaa I. El‐Eraky, Ragab Said, Sally A. El Awdan, Mohamed Ali, Ayman Al‐Hendy and Kornelia Zaręba. Their work appears in journals such as Pharmaceutics, Expert Opinion on Drug Safety, Vaccines, AAPS PharmSciTech and Advances in experimental medicine and biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.